A recent study indicates that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Findings released in a prominent medical journal shows that while overweight individuals frequently drop substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such treatments must be cognizant of the potential of rapid rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
This pace of recovery suggests a return to original mass in about 18 months.
Weighing Therapies
The study, which examined 37 of trials involving thousands of participants, compared the outcomes of the injectable medications with other pills.
The team note that people who shed pounds through lifestyle changes alone typically have a less rapid weight regain—around 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Experts suggest the way of the injections is key to understanding the amplified weight return.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the system to produce less of its endogenous hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to appetite is unsuppressed, making overeating much more probable."
A Chronic Issue?
The NHS advise the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts contend that, considering the high risk of relapse, the therapy is often life-long.
This perspective is supported by drug manufacturers, who state that the findings "underscore the chronic character of excess weight," akin to managing diseases like hypertension.
User Accounts
Users who have come off the jabs report a intense return of appetite.
"I experienced a trigger that goes on and I was suddenly starving," recalled an individual.
The struggle is worsened if patients have not adopted sustainable lifestyle or habit changes during treatment.
Growing Use
Survey data show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among women than men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on combined lifestyle management.
